CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 30 enrolled
Drug / intervention
glecaprevir/pibrentasvir treatmentdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03781726
NCT03781726Phase 4Completed
CompareCT.gov

A Multi-Center, Open-Label Study of Glecaprevir/Pibrentasvir to Treat Recipients of Transplanted Kidneys From Deceased Donors With Hepatitis C Virus

Raymond Chung·interventional·Posted Dec 20, 2018·Updated Jan 26, 2022

In Brief

A Phase 4 clinical trial evaluating glecaprevir/pibrentasvir treatment for Renal Failure Chronic and Hepatitis C. Completed, enrolled 30 participants across 7 sites.

Detailed Summary

Open label multi center study for the donation of HCV positive kidneys to HCV negative recipients with interventional treatment to prevent HCV transmission upon transplantation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Failure Chronic, Hepatitis C
CountriesUnited States
CollaboratorsAbbVie, University of Pennsylvania, Johns Hopkins University, University of Cincinnati, Weill Medical College of Cornell University, University of Michigan, Northwestern University

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedDec 20, 2018
Enrollment StartApr 10, 2019
Primary CompletionMar 20, 2020
Study CompletionDec 31, 2021
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 7.5 years ago

Interventions

glecaprevir/pibrentasvir treatmentdrug

combination treatment with glecaprevir and pibrentasvir fixed dose tablet.